A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment

Plain-language summary

Published 2024 in Geroscience, this work by Orr ME and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

• Human study published in Geroscience (2024) examining A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild c...
• Provides clinical-grade evidence on NAD+/NMN-related outcomes in human participants
• First author: Orr ME; cited frequently in NMN supplementation discussions

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to benefits decisions, with secondary relevance to compare. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.